Madrigal Pharmaceuticals (NASDAQ: MDGL)
Madrigal Pharmaceuticals Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Madrigal Pharmaceuticals Company Info
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.
News & Analysis
Here's 1 Huge New Reason to Buy Madrigal Pharmaceuticals Stock
This biotech just got clearance to dive into a deep ocean of a market.
This Under-the-Radar Stock Just Hit a Major Milestone: Time to Buy?
The mid-cap biotech has succeeded where many others failed.
Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win?
Madrigal has one key advantage over its two huge potential future rivals.
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.
1 Wall Street Analyst Thinks Madrigal Pharmaceuticals Stock Is Going to $347. Is It a Buy Around $247?
This business could be on the cusp of making medical history.
1 Beaten-Down Stock That Could Soar by 40%, According to Wall Street
The company might have a bright future, but is now the right time to buy shares?
2 Rising Biotechs That Could Become the Next Novo Nordisk
Each of these companies has a big market in its sights.
2 Stocks That Could Soar This Year: Are They Buys?
They might perform well in 2024, but how will they do beyond that?
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.